目的 探讨慢性肝病患者发生肝性脑病(hepatic encephalopathy, HE)的危险因素。方法 以2014—2019年医院收治的64例HE患者为研究对象。以HE患者首次明确诊断为肝炎或肝硬化的时间为研究起点,首次发作HE作为研究终点,通过单因素和多因素分析,探讨引发HE可能的独立危险因素。结果 单因素和多因素分析表明,年龄(OR:1.066,P<0.0001)、肝硬化(7.979,P<0.0001)、乙肝病毒(HBV)感染及治疗(5.838,P<0.0001)、脾脏肿大(2.722,P=0.003)、食管胃底静脉曲张(EGV, 1.986,P=0.024)和ALT水平高低(2.940,P<0.0001)是影响HE 发病的独立危险因素。肝病患者HE 1年、3年、5年、10年的发病率分别是14.06%、34.38%、42.19%和85.94%。结论 年龄、肝硬化、HBV感染及治疗、脾大、EGV和血清ALT水平是潜在预判肝病患者HE发作的临床指标。
Abstract
Objective To explore the independent risk factors for hepatic encephalopathy (HE) in patients with liver diseases. Methods Sixty-four patients with HE who visited our hospital between 2014 and 2019 were enrolled in this study. These patients were divided into two groups: the male group (n=51) and female group(n=13). The clinical characteristics were compared between the two groups so as to find the difference between the two genders. The first definitive diagnosis of hepatitis or cirrhosis was taken as the starting point and the first attack of HE as the end point. Possible independent risk factors for HE were explored based on univariate and multivariate analysis. Results Univariate and multivariate analysis showed that age (OR: 1.066, P<0.0001), cirrhosis (7.979, P< 0.0001), hepatitis B virus infection and treatment (5.838, P<0.0001), splenomegaly (2.722, P= 0.003), esophagogastric varices (EGV, 1.986, P= 0.024) and ALT level (2.940, P<0.0001) were independent risk factors for HE. The 1-, 3-, 5- and 10-year incidence of HE was 14.06%, 34.38%, 42.19% and 85.94%, respectively. Conclusions Male HE patients have more of a pathological basis of cirrhosis and higher serum total bilirubin levels than female ones during the early stage. Age, cirrhosis, hepatitis B virus infection and anti-virus treatment, splenomegaly, EVG and serum ALT levels are potential clinical indicators for predicting HE attack in patients with liver diseases.
关键词
肝性脑病 /
危险因素 /
肝病
Key words
hepatic encephalopathy /
risk factors /
liver diseases
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J].Hepatology,2014,60(2):715-735.
[2] Hsu S J, Zhang C, Jeong J,et al. Enhanced meningeal lymphatic drainage ameliorates neuroinflammation and hepatic encephalopathy in cirrhotic rats[J].Gastroenterology,2021,160(4):1315-1329.
[3] Luo S, Zhou Z M, Guo D J, et al. Radiomics-based classification models for HBV-related cirrhotic patients with covert hepatic encephalopathy[J].Brain and Behavior,2021,11(2):1-11.
[4] Chepkova A N, Sergeeva O A, Haas H L. Taurine rescues hippocampal long-term potentiation from ammonia-induced impairment[J].Neurobiol Dis,2006,23(3):512-521.
[5] Hassan A, Tsuda Y, Asai A, et al. Effects of oral l-carnitine on liver functions after transarterial chemoembolization in intermediate-stage HCC patients[J]. Mediators Inflamm,2015,20(1):1-11.
[6] Boer L A, Panatto J P, Fagundes D A, et al. Inhibition of mitochondrial respiratory chain in the brain of rats after hepatic failure induced by carbon tetrachloride is reversed by antioxidants[J].Brain Res Bull,2009,80(1-2):75-78.
[7] Milewski K, Hilgier W, Fresko I, et al. Carnosine reduces oxidative stress and reverses attenuation of righting and postural reflexes in rats with thioacetamide-induced liver failure[J].Neurochem Res,2016, 41(1-2):376-384.
[8] Bémeur C, Vaquero J, Desjardins P, et al. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms[J].Metab Brain Dis,2010,25(2):241-249.
[9] Farshad O, Keshavarz P, Heidari R, et al. The potential neuroprotective role of citicoline in hepatic encephalopathy[J].J Exp Pharmacol,2020,12(1):517-527.
[10] 王建伟,刘素梅,杨宵曼,等.乙型肝炎肝衰竭患者发生肝性脑病的危险因素分析[J].中国实用神经疾病杂志,2017,20(2):69-71.
[11] Rose C F,Amodio P,Bajaj J S, et al. Hepatic encephalopathy: novel insights into classification,pathophysiology and therapy[J].J Hepatol,2020,73(6):1526-1547.
[12] 徐小元,段钟平.肝硬化肝性脑病诊疗指南[J].西南医科大学学报,2018, 41(6):477-490.
[13] 王贵强,王福生,庄 辉,等.慢性乙型肝炎防治指南年版[J].临床肝胆病杂志,2019,35(12):2648-2669.
[14] Ishii N, Mochizuki H, Sakai K, et al. Parkinsonism and high-intensity midbrain lesions on T2-weighted imaging in hepatic encephalopathy: a case report[J].Neurological Sciences,2017,38(8):1547-1549.
[15] Jayakumar A R, Norenberg M D. Glutamine synthetase, role in neurological disorders[J]. Adv Neurobiol,2016,13(1):327-350.
[16] Desjardins P, Du T, Jiang W, et al. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: role of glutamine redefined[J].Neurochem Int,2012,60(7):690-696.
[17] 王小琴,杨小丽.乙型肝炎肝硬化合并肝性脑病的危险因素[J].肝脏,2019,24(11):1328-1329.
[18] Cui Y, Guan S, Ding J, et al.Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy[J].Metabolic Brain Disease,2019,34(1):213-221.
[19] Strebel H, Haller B, Sohn M, et al. Role of brain biomarkers S-100-Beta and neuron-specific enolase for detection and follow-up of hepatic encephalopathy in cirrhosis before,during and after treatment with L-Ornithine-L-Aspartate[J].GE - Portuguese Journal of Gastroenterology,2020,27(6):391-403.
[20] Tong H, Gan C, Wei B, et al. Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis[J]. Journal of Digestive Diseases,2021,22(1):31-40.
[21] Chen S, Huang H, Liu Y, et al. A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infection[J].Cancer Cell Int,2020, 20(1):555.
[22] Nie Y, Deng X, Lan Y, et al. Comparison and correlation of genetic variability of the HBV Pre-S region in HIV/HBV co-infected patients: quasispecies perspective[J].Infection and Drug Resistance,2020,13(1):4327-4334.
[23] Napolitano M, Franchi-Abella S, Damasio M B, et al. Practical approach to imaging diagnosis of biliary atresia, Part 1: prenatal ultrasound and magnetic resonance imaging, and postnatal ultrasound[J]. Pediatr Radiol,2021,51(2):314-331.
[24] Kumar R, Kerbert A, Sheikh M F, et al. Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding[J].J Hepatol,2021,74(1):66-79.
PDF(591 KB)
